These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29362358)

  • 1. Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.
    Sato H; Sakaguchi M; Yamamoto H; Tomida S; Aoe K; Shien K; Yoshioka T; Namba K; Torigoe H; Soh J; Tsukuda K; Tao H; Okabe K; Miyoshi S; Pass HI; Toyooka S
    Oncogenesis; 2018 Jan; 7(1):11. PubMed ID: 29362358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling.
    Roshini A; Goparaju C; Kundu S; Nandhu MS; Longo SL; Longo JA; Chou J; Middleton FA; Pass HI; Viapiano MS
    Front Oncol; 2022; 12():1014749. PubMed ID: 36303838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
    Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
    Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
    Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active Secretion of Dimerized S100A11 Induced by the Peroxisome in Mesothelioma Cells.
    Saho S; Satoh H; Kondo E; Inoue Y; Yamauchi A; Murata H; Kinoshita R; Yamamoto KI; Futami J; Putranto EW; Ruma IM; Sumardika IW; Youyi C; Suzawa K; Yamamoto H; Soh J; Tomida S; Sakaguchi Y; Saito K; Iioka H; Huh NH; Toyooka S; Sakaguchi M
    Cancer Microenviron; 2016 Dec; 9(2-3):93-105. PubMed ID: 27334300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
    Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
    Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs dysregulation in human malignant pleural mesothelioma.
    Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
    J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
    Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
    Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
    BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
    Bruno R; Alì G; Fontanini G
    J Thorac Dis; 2018 Jan; 10(Suppl 2):S342-S352. PubMed ID: 29507804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma.
    Hagiyama M; Mimae T; Wada A; Takeuchi F; Yoneshige A; Inoue T; Kotoku N; Hamada H; Sekido Y; Okada M; Ito A
    Front Cell Dev Biol; 2022; 10():945007. PubMed ID: 35903548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.
    Martarelli D; Catalano A; Procopio A; Orecchia S; Libener R; Santoni G
    BMC Cancer; 2006 May; 6():130. PubMed ID: 16704740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
    Mazieres J; You L; He B; Xu Z; Twogood S; Lee AY; Reguart N; Batra S; Mikami I; Jablons DM
    Int J Cancer; 2005 Nov; 117(2):326-32. PubMed ID: 15900580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
    Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
    Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K; Serada S; Fujimoto M; Nomura S; Osaki T; Lee CM; Mizuguchi H; Takahashi T; Ripley B; Okumura M; Kawase I; Kishimoto T; Naka T
    Int J Cancer; 2011 Aug; 129(4):1005-17. PubMed ID: 20949562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma.
    Zhou L; El-Deiry W; Wang W; Ingram ME; Katz SI
    Oncol Rep; 2012 Sep; 28(3):883-8. PubMed ID: 22751990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.
    Kubo T; Toyooka S; Tsukuda K; Sakaguchi M; Fukazawa T; Soh J; Asano H; Ueno T; Muraoka T; Yamamoto H; Nasu Y; Kishimoto T; Pass HI; Matsui H; Huh NH; Miyoshi S
    Clin Cancer Res; 2011 Aug; 17(15):4965-74. PubMed ID: 21673066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.